Ritlecitinib (Litfulo) for alopecia areata: how it works, the 3-year results and what its Malaysian registration means

Ritlecitinib (Litfulo) is a once-daily JAK3 and TEC inhibitor for severe alopecia areata from age 12, and it is registered in Malaysia. How it works, what the ALLEGRO trial and the three-year and five-year data show, the screening and blood tests, a realistic timeline and how to discuss it with a dermatologist.

Rambut editorial team ·

Alopecia areata can take hair away suddenly, in round patches or, for some people, across the whole scalp, the eyebrows and the eyelashes. For years the options for severe cases were limited to steroid injections, steroid tablets for short periods and immune treatments with modest results. That changed when a group of tablets called JAK inhibitors arrived. Ritlecitinib, sold as Litfulo, is one of them, and it is the first in the group approved for teenagers as young as 12 in the United States 1. It is also registered in Malaysia 2.

This guide explains how alopecia areata works, how ritlecitinib differs from the other JAK inhibitors, what the main trial and the newer three-year and five-year data show, the safety checks involved, a realistic timeline and what the Malaysian registration means in practice. It is general information, not personal medical advice. For background, see alopecia areata, JAK inhibitors for alopecia areata and upadacitinib for alopecia areata.

The short answer

Ritlecitinib is a once-daily 50 mg capsule for severe alopecia areata in people aged 12 and over 3. In the main trial, 23% of people on 50 mg had at least 80% of the scalp covered with hair after 24 weeks, compared with 1.6% on placebo 1 4. In longer follow-up, about two in three people who kept taking it had reached that level at three years, counting only those still in the study 5. It carries a boxed warning about serious infections, cancer, heart events and blood clots that applies to the JAK inhibitor group, needs blood tests and screening for TB and hepatitis first, and must not be used in pregnancy 3 6. It calms the immune attack rather than ending the condition, and hair can fall again if it is stopped. In Malaysia it is a registered prescription medicine, so the route is a dermatologist, not a pharmacy shelf or an online seller 2 7.

Alopecia areata in brief

Each hair follicle normally hides from the immune system. Scientists call this "immune privilege". In alopecia areata that protection breaks down. Immune cells, mainly a type of CD8 T cell, gather around the base of growing follicles and release signals such as interferon gamma. Other signals, including interleukin 15, keep these cells active. The follicle is pushed out of its growing phase (anagen) too early, the hair shaft becomes weak and breaks or falls, and the patch goes bald 8 9.

The key point is that the follicle is not destroyed. Alopecia areata is a non-scarring condition, which is why hair can grow back, either on its own or with treatment, sometimes after years 8 10. It is also why the disease can relapse: the immune attack can return.

Doctors describe a few patterns:

  • Patchy alopecia areata, with one or more round or oval bald patches. Short "exclamation mark" hairs at the edge are a classic sign 10.
  • Alopecia totalis, with loss of all or nearly all scalp hair.
  • Alopecia universalis, with loss of scalp, face and body hair.
  • Ophiasis, a band of loss along the sides and back of the scalp, which tends to be harder to treat 8.

Severity is usually measured with the SALT score, the Severity of Alopecia Tool. It estimates the percentage of scalp without hair. A SALT score of 100 means a fully bald scalp. A SALT score of 20 or less means at least 80% of the scalp has hair, which most trials use as their main target. A SALT score of 10 or less means at least 90% coverage 4.

How ritlecitinib works

Many of the immune signals in alopecia areata travel inside cells through a relay system called JAK-STAT. When a signal molecule docks on a cell, JAK enzymes pass the message to STAT proteins, which switch on inflammatory genes. Blocking JAK enzymes turns that relay down 11.

There are four JAK enzymes. Different medicines in the group block different ones:

  • Baricitinib blocks mainly JAK1 and JAK2 12 11.
  • Upadacitinib blocks mainly JAK1 13.
  • Ritlecitinib irreversibly blocks JAK3 and a second family of enzymes called TEC kinases 3.

JAK3 carries signals from a group of receptors used by interleukin 15 and related cytokines, which help keep the attacking T cells active. TEC kinases are involved in signals from T cell and natural killer cell receptors. By blocking both, ritlecitinib is thought to calm the cells that attack the follicle 1 3. The prescribing information is careful to say that the exact importance of each target for hair growth is not yet known 3. In trials, people taking it had an early fall in lymphocyte counts, which is one reason blood tests are part of treatment 3.

Whether this narrower target makes ritlecitinib safer or more effective than other JAK inhibitors is an open question. No trial has compared them head to head 11.

What the ALLEGRO trial found

The main study, ALLEGRO phase 2b/3, was published in The Lancet in 2023. It took place at 118 sites in 18 countries and enrolled 718 people aged 12 and over with at least 50% scalp hair loss, including people with alopecia totalis and universalis. About a quarter (26%) were Asian, and 62% were female 4. The current episode had to have lasted between six months and ten years 1.

People were randomly given ritlecitinib at different doses, some with a four-week 200 mg starting dose, or placebo. After 24 weeks, the share reaching SALT 20 or less was 4:

  • 31% with a 200 mg loading dose then 50 mg
  • 23% with 50 mg daily
  • 22% with a 200 mg loading dose then 30 mg
  • 14% with 30 mg daily
  • 2% with placebo

The approved dose is 50 mg once daily without a loading dose 3. With that dose, the European Medicines Agency summary reports that 13% reached at least 90% scalp coverage at 24 weeks, rising to 31% at 48 weeks. When people were asked whether their alopecia had improved, 49% on ritlecitinib said it was moderately or greatly better, compared with 9% on placebo 6.

Most people did not reach the 80% target by six months, and results were still rising at 48 weeks, so a fair trial takes most of a year. In Europe, the product information says treatment should be stopped if there is no improvement after 36 weeks 6.

The longer-term picture: three and five years

Many participants rolled over into an open-label extension study, ALLEGRO-LT. A 2026 analysis followed 191 people who stayed on 50 mg 5:

  • At three years, 65.1% of those still in the study had SALT 20 or less. When people who left the study were counted using their last result, the figure was 47.1%.
  • 52.3% had SALT 10 or less (36.7% counting dropouts).
  • 31.2% had a SALT score of 0, meaning full scalp coverage (22.5% counting dropouts).
  • Of those who reached SALT 20 or less at one year, about 88% to 90% still met it at three years.

The authors found that women, people with less extensive hair loss at the start and people whose current episode was shorter were more likely to respond. White participants also responded more often than other groups, a finding that needs more study in Asian populations 5.

People who drop out of long studies are often those not doing well, so the honest reading sits between the two figures.

Adolescents

A separate analysis looked at 57 teenagers aged 12 to 17 who rolled over into the long-term study. Through 24 months, 42.1% reached SALT 20 or less, some early, some later. The rest were partial responders, relapsers or did not respond. Teenagers who responded tended to have shorter episodes and were less likely to have alopecia totalis or universalis 14. For families, that means a real chance of benefit, but not a predictable one.

Five-year safety

An integrated safety analysis pooled 1,228 people on the 50 mg regimen, with a median of about three and a quarter years on treatment. The most common side effects were headache, a positive COVID-19 test and colds. Serious adverse events occurred in 6.8%, and 8.1% stopped because of a side effect. Rates per 100 person-years were 1.0 for shingles, 0.3 for cancers other than common skin cancers, 0.2 for major heart events and 0.1 for opportunistic infections. There were two deaths across the programme. The authors reported no new safety signals 15.

Comparison table: options for alopecia areata

OptionHow it worksUsually suited toEvidenceMain drawbacks
Watchful waitingMany small patches settle without treatmentOne or a few small, recent patchesNatural history dataUnpredictable, may spread
Steroid injections into patchesCalms inflammation locallyLimited patchy disease in adultsLong clinical useRepeated injections, skin dents, impractical for large areas
Topical steroids or contact immunotherapyLocal anti-inflammatory or immune redirectionPatchy disease, childrenMixed, smaller studiesSlow, irritation
Baricitinib (JAK1 and JAK2)Blocks JAK signallingSevere disease in adultsTwo phase 3 trialsClass boxed warning, lab tests, relapse on stopping
Ritlecitinib (JAK3 and TEC)Blocks JAK3 and TEC signallingSevere disease, age 12 and overOne phase 2b/3 trial plus long-term dataClass boxed warning, lab tests, pregnancy exclusion, relapse on stopping
Upadacitinib (mainly JAK1)Blocks mainly JAK1Severe disease, adults and adolescents where approvedTwo phase 3 trialsClass boxed warning, acne, infections
Wigs, hair systems, SMP, brow and lash optionsCamouflage onlyAnyone, with or without medicineCosmeticDoes not change the disease

Sources: 16 17 12 4 13.

Who a dermatologist might consider

Ritlecitinib is approved for severe alopecia areata 6 3. In the main trial that meant at least 50% scalp hair loss 4. A dermatologist will usually weigh:

  • the extent of hair loss and how long the current episode has lasted, since shorter episodes respond better 5
  • age, because it is approved from 12 years old
  • past infections, TB exposure, hepatitis B or C, blood counts, heart and clot risk factors, and cancer history 3
  • pregnancy plans, because it must not be used in pregnancy or while breastfeeding 6
  • other medicines, since it is not recommended with other JAK inhibitors, biologic immune medicines or strong immunosuppressants 3

It is not a treatment for pattern hair loss, stress shedding or hair breakage. If the diagnosis is uncertain, a dermatologist may use trichoscopy or, occasionally, a scalp biopsy.

Safety: the boxed warning and the checks

Like every oral JAK inhibitor, ritlecitinib carries a US boxed warning covering serious infections, death, cancer, major heart events and blood clots. Part of this warning comes from a study of another JAK inhibitor in people with rheumatoid arthritis, compared with a different class of medicine, but it is applied to the whole group 3.

Before starting, the prescribing information recommends 3:

  • testing for latent TB, and treating it first if found
  • screening for hepatitis B and C, since starting is not recommended in people with either
  • a full blood count, because treatment should not start if lymphocytes are below 500 per cubic millimetre or platelets are below 100,000 per cubic millimetre
  • bringing vaccinations up to date, and avoiding live vaccines during or shortly before treatment

During treatment, blood counts are repeated. Treatment is interrupted if lymphocytes fall below 500 and stopped if platelets fall below 50,000 3.

The most common side effects in the trial were headache (10.8%), diarrhoea (10%), acne (6.2%), rash (5.4%) and hives (4.6%) 1. Other reported effects include folliculitis, fever, dizziness, a rise in a muscle enzyme called CPK and shingles 3. People with diabetes are told to watch for low blood sugar 3.

Seek medical help quickly for fever, cough, painful blistering rash, chest pain, sudden breathlessness, leg swelling, or weakness on one side of the body.

Step by step: what to expect

  1. Diagnosis. A dermatologist confirms alopecia areata and measures severity, often with photos and a SALT score.
  2. Discussion of options. Injections, topical treatment, JAK inhibitors and camouflage are weighed against the extent of loss, age, health and cost.
  3. Screening. TB test, hepatitis screening, full blood count and other tests as needed, plus a vaccine review.
  4. Starting. One 50 mg capsule a day, swallowed whole, with or without food 3.
  5. Early months. Blood counts are rechecked. Any new growth may start as fine, light hairs.
  6. Six to twelve months. This is the main window for judging response. In Europe, treatment is stopped if there is no improvement after 36 weeks 6.
  7. Long term. If it works, the medicine is usually continued with regular review. A short break of less than six weeks is not expected to cause major loss of the new scalp hair, according to the US prescribing information 3. Longer breaks may allow the disease to return.

Typical timeline

Time on treatmentWhat the data suggest
0 to 3 monthsScreening, blood tests, often little visible change
About 6 months23% on 50 mg reached at least 80% scalp coverage in the trial 4
About 12 months31% on 50 mg reached at least 90% coverage 6
3 years65.1% of those still taking it had at least 80% coverage (47.1% counting dropouts) 5

Everyone is different, and these are averages from trials, not predictions for one person.

Malaysian context

Malaysia's Drug Control Authority approved Litfulo 50 mg hard capsules at its meeting on 3 October 2024, with registration number MAL24106010ARZ held by Pfizer (Malaysia) 2. The letter A after the eight digits marks a controlled medicine, which in practice means a doctor's prescription 7. Anyone can check a product on the NPRA QUEST search 18 and check a doctor on the Malaysian Medical Council register 19.

Registration does not tell you the price, stock or insurance cover. No verified public price source exists, so ask the hospital for a written estimate covering consultations, screening, follow-up blood tests and the medicine. Because JAK inhibitors are taken long term, the yearly cost matters more than the first month.

About a quarter of the main trial's participants were Asian 4, but there is little published data specifically from Malaysian patients. The three-year analysis also found that response differed by race, which is a reason for a careful, individual discussion rather than assuming trial averages will apply 5.

In hot, humid weather, wigs and hair systems can feel warm, so breathable bases matter while waiting for medicine to work, and bald patches need sun protection. Visible hair loss also weighs on mood, and support helps. See hair loss and anxiety and wigs and hair pieces.

For assessment, start with a dermatologist at a government or private hospital, who can confirm the diagnosis and advise whether a JAK inhibitor suits you. Folk explanations such as "ghost shave" beliefs are common, but alopecia areata is an immune condition with real medical options.

Common myths

  • "JAK inhibitors work for every kind of hair loss." Ritlecitinib is approved only for severe alopecia areata. It is not a pattern hair loss treatment 6.
  • "Once the hair is back, the medicine can be stopped." Alopecia areata can return after stopping. Long-term data come from people who kept taking it 5.
  • "It is just a hair pill, so no tests are needed." It is an immune medicine that requires TB and hepatitis screening and blood counts 3.
  • "If nothing happens in two months, it has failed." Responses often build through the first year 6.

Practical checklist

  • Confirm the diagnosis with a dermatologist, and ask for your SALT score.
  • Ask whether your hair loss counts as severe and whether you are a candidate for a JAK inhibitor.
  • Tell the doctor about past TB, hepatitis, shingles, blood clots, heart disease, cancer and diabetes.
  • List every medicine and supplement you take.
  • Plan contraception if you could become pregnant.
  • Check vaccinations before starting.
  • Get a written estimate of yearly costs.
  • Take dated photos of the scalp, brows and lashes every month.
  • Agree a review point at around six to nine months.
  • Buy medicine only through a doctor or registered pharmacy, never online marketplaces.

Summary

Ritlecitinib is a once-daily JAK3 and TEC inhibitor for severe alopecia areata in people aged 12 and over. In its main trial about a quarter of people on the approved dose reached 80% scalp coverage at six months, and long-term data show many responders keep their hair while they stay on treatment, with no new safety signals over about five years 4 5 15. It still needs screening, blood tests and careful thought about infection, heart, clot and pregnancy risks 3. It is registered in Malaysia, so the path is a dermatologist who can weigh it against injections, other JAK inhibitors and camouflage options for your situation 2. Results vary from person to person.

Frequently asked questions

What is ritlecitinib?

Ritlecitinib, sold as Litfulo, is a once-daily 50 mg capsule that blocks JAK3 and TEC kinases. It is approved for severe alopecia areata in adults and adolescents aged 12 and over 3 6.

How well does it work?

In the main trial, 23% of people on 50 mg reached at least 80% scalp coverage at 24 weeks, compared with 1.6% on placebo. At 48 weeks, 31% had at least 90% coverage 1 6.

How long before I see results?

Often several months. Results kept building through the first year, and in Europe treatment is stopped if there is no improvement after 36 weeks 6.

Is ritlecitinib available in Malaysia?

Yes. Litfulo 50 mg capsules were registered by the Drug Control Authority in October 2024 (MAL24106010ARZ). It is a prescription medicine, so it is obtained through a doctor 2 7.

What tests are needed before starting?

Testing for latent TB, hepatitis B and C screening, a full blood count and a vaccination review. Blood counts are repeated during treatment 3.

What are the common side effects?

Headache, diarrhoea, acne, rash and hives were the most common in the trial. Shingles and other infections can occur, and it carries the JAK inhibitor boxed warning 1 3.

Will my hair fall out again if I stop?

It can. Alopecia areata can return after stopping, and long-term results come from people who kept taking it. A short break of under six weeks is not expected to cause major loss 3 5.

Sources

  1. Pfizer. FDA Approves Pfizer's LITFULO (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata, 2023. accessed 27 Oct 2026
  2. National Pharmaceutical Regulatory Agency (NPRA), Malaysia. Senarai produk ubat baru yang didaftarkan oleh PBKD pada tahun 2024, 2024. accessed 27 Oct 2026
  3. Pfizer (US prescribing information). LITFULO (ritlecitinib) capsules: full prescribing information, 2026. accessed 27 Oct 2026
  4. PubMed. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial, Lancet, 2023. accessed 27 Oct 2026
  5. PubMed (Senna et al., Am J Clin Dermatol, 2026). Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies, 2026. accessed 27 Oct 2026
  6. European Medicines Agency. Litfulo (ritlecitinib): EPAR medicine overview, 2023. accessed 27 Oct 2026
  7. Pharmaceutical Services Programme, Ministry of Health Malaysia. How to identify medicines that are registered with MOH?. accessed 27 Oct 2026
  8. PubMed. Alopecia areata, Nat Rev Dis Primers, 2025. accessed 27 Oct 2026
  9. American Academy of Dermatology. Alopecia areata: Causes. accessed 27 Oct 2026
  10. American Academy of Dermatology. Alopecia areata: Signs and symptoms. accessed 27 Oct 2026
  11. PubMed. Janus kinase inhibitors for alopecia areata, J Am Acad Dermatol, 2023. accessed 27 Oct 2026
  12. PubMed. Two Phase 3 Trials of Baricitinib for Alopecia Areata, N Engl J Med, 2022. accessed 27 Oct 2026
  13. JAMA Dermatology (via PubMed Central). Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials, 2026. accessed 27 Oct 2026
  14. PubMed (Blume-Peytavi et al., Dermatol Ther, 2026). Patterns of Clinical Response in Rollover Adolescent Patients with Alopecia Areata Treated with Ritlecitinib in the Ongoing Long-Term, Open-Label, Phase 3 ALLEGRO-LT Study, 2026. accessed 27 Oct 2026
  15. PubMed (Am J Clin Dermatol, 2026). Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program, 2026. accessed 27 Oct 2026
  16. American Academy of Dermatology. Alopecia areata: Diagnosis and treatment. accessed 27 Oct 2026
  17. PubMed. Treatments for alopecia areata: a network meta-analysis, Cochrane Database Syst Rev, 2023. accessed 27 Oct 2026
  18. National Pharmaceutical Regulatory Agency (NPRA), Malaysia. QUEST 3+ Product Search. accessed 27 Oct 2026
  19. Malaysian Medical Council. Malaysian Medical Council (registered medical practitioners and specialists). accessed 27 Oct 2026

Educational content. Not medical advice.

Related reading

Hair Loss

Alopecia areata (patchy hair loss): a clear explainer

An in-depth guide to alopecia areata (botak tompok): the immune biology, types, diagnosis and look-alikes, what to do when you find a patch, a timeline, treatment options compared with pros and risks, camouflage and coping, the Malaysian context, myths and a checklist.

Rambut editorial team ·

Hair Loss

Can alopecia areata go away on its own?

Can alopecia areata go away on its own? Often, especially small recent patches, but no one can predict it. What affects the outlook, when to wait, when to treat and how to track patches.

Rambut editorial team ·

All articles